| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Ewing Sarcoma in Children -
COG #AEWS07B1: A COG STUDY FOR COLLECTING AND BANKING EWING SARCOMA SPECIMENS
(1_20080710_118)
This study will collect tumor blood, bone marrow and tumor specimens as well as demographic and clinical data, which will be stored for researchers to use for testing at a later date.
- Ewing Sarcoma in Children -
COG #AEWS07P1: A PILOT STUDY OF CHEMOTHERAPY INTENSIFICATION BY ADDING VINCRISTINE, TOPOTECAN AND CYCLOPHOSPHAMIDE TO STANDARD CHEMOTHERAPY AGENTS WITH AN INTERVAL COMPRESSION SCHEDULE IN NEWLY DIAGNOSED PATIENTS WITH LOCALIZED EWING SARCOMA FAMILY OF TUMORS
(1_20080909_118)
Participants will receive an experimental combination and dosage, the Induction for 6 cycles, which will be for weeks 1-12. Following the Induction cycles, the participants will be evaluated. If the participant has progressive disease the patient will then be taken off protocol. If the participant is having local control with the therapy, the participant may go on for surgery and or radiation therapy and may extend into Continuation therapy. The Continuation therapy will be for 11 cycles of chemotherapy, weeks 15-36. Participants will be evaluated throughout the 11 Continuation cycles and if found to have disease progression will be taken off protocol.
- ISOLATED LIMB INFUSION REGISTRY PROTOCOL
(2_20080910_118)
This study is to open a data base for any patient who has or will have Isolated Limb Infusions of a leg or arm. This study is for participants with melanoma and/or sarcoma. This registry study will have no end date, it will be ongoing.
- Osteosarcoma in Children -
COG #AOST0331: A RANDOMIZED TRIAL OF THE EUROPEAN AND AMERICAN OSTEOSARCOMA STUDY GROUP TO OPTIMIZE TRETMENT STRATEGIES FOR RESECTABLE OSTEOSARCOMA BASED ON HISTOLOGICAL RESPONSE TO PRE-OPERATIVE CHEMOTHERAPY
(1_20081010_118)
This study is for children and young adults with a surgically resectable osteosarcoma. Participants will be given standard treatment with MAP therapy. After 10 weeks of chemotherapy the tumor will be surgically resected. If 90% or more of the tumor is dead, this is considered a good response; less than the 90% is considered a bad response and the chance of cure is not as good. For participants whose response is considered bad, they will then be offered additional drugs, ifosfamide and etoposide with MAP; for participants who have a good response they will be given interferon with MAP.
- Sarcoma - Multiple Sites:
COG: ARST0531, Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
(2_20090712_118)
There will be two arms to this study: Arm A will be given standard therapy VAC; and Arm B will treat with VAC alternating with VI. All participants will receive radiation therapy beginning at week 4. Treatments will consist of 14 cycles for bother arm; each cycle lasting 3 weeks. Total treatment time on the study if 43 weeks. Follow-up exams will be done every 2-4 months for the first 4 years and then yearly for years 5-10 following completion of protocol therapy.
- Study Closed to Accrual: Sarcoma in Children - COG: ARST0431: INTENSIVE MULTI-AGENT THERAPY, INCLUDING DOSE-COMPRESSED CYCLES OF IFOSFAMIDE/ETOPOSIDE (IE) AND VINCRISTINE/DOXORUBICIN/CYCLOPHOSPHAMIDE (VDC) FOR PATIENTS WITH HIGH-RISK RHABDOMYOSARCOMA: A GROUP PHASE II STUDY (2_20070713_118)
Patients will start out with Chemotherapy. After 1 cycle participants will be evaluated for any evidence of disease progression. If there is disease progression after 1 cycle the patient will be removed from study. If no disease progression after first cycle, participants will receive a second cycle followed by evaluation. If no disease progression following the second cycle, the participant will go on to complete a total of 6 cycles. After the 6 cycles, the participant will be evaluated for disease progression, if none the patient will go on for radiation therapy plus chemotherapy for 6 more cycles. If no disease progression following the combination of radiation therapy and chemotherapy, the participant may continue on for an additional 6 cycles of chemotherapy. Upon the completion of this last set of 6 cycles the study will end.
|
|
